{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T18:00:35Z","timestamp":1771956035569,"version":"3.50.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10147-025-02955-3","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:18:14Z","timestamp":1767849494000},"page":"381-382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; imlunestrant for breast cancer, tafasitamab for follicular lymphoma, atezolizumab for thymic carcinoma, retifanlimab for anal canal squamous cell carcinoma, and tagraxofusp for blastic plasmacytoid dendritic cell neoplasm"],"prefix":"10.1007","volume":"31","author":[{"given":"Noriomi","family":"Matsumura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"2955_CR1","unstructured":"Pharmaceuticals and Medical Devices Agency (2025) List of approved drugs (in Japanese). https:\/\/www.pmda.go.jp\/review-services\/drug-reviews\/review-information\/p-drugs\/0010.html Accessed 23 Dec 2025"},{"key":"2955_CR2","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","volume":"392","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri KL, Neven P, Casalnuovo ML et al (2025) Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 392:1189\u20131202. https:\/\/doi.org\/10.1056\/NEJMoa2410858","journal-title":"N Engl J Med"},{"key":"2955_CR3","doi-asserted-by":"publisher","unstructured":"Sehn LH, H\u00fcbel K, Luminari S, et al (2026) Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial. Lancet. Published online ahead of print. https:\/\/doi.org\/10.1016\/S0140-6736(25)01778-7.","DOI":"10.1016\/S0140-6736(25)01778-7"},{"key":"2955_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S1470-2045(25)00001-4","volume":"26","author":"T Shukuya","year":"2025","unstructured":"Shukuya T, Asao T, Goto Y et al (2025) Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial. Lancet Oncol 26:331\u2013342. https:\/\/doi.org\/10.1016\/S1470-2045(25)00001-4","journal-title":"Lancet Oncol"},{"key":"2955_CR5","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/S0140-6736(25)00631-2","volume":"405","author":"S Rao","year":"2025","unstructured":"Rao S, Samalin-Scalzi E, Evesque L et al (2025) Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303\/InterAACT-2): a global, phase 3 randomised controlled trial. Lancet 405:2144\u20132152. https:\/\/doi.org\/10.1016\/S0140-6736(25)00631-2","journal-title":"Lancet"},{"key":"2955_CR6","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","volume":"380","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, Lane AA, Sweet KL et al (2019) Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med 380:1628\u20131637. https:\/\/doi.org\/10.1056\/NEJMoa1815105","journal-title":"N Engl J Med"},{"key":"2955_CR7","unstructured":"Nippon Shinyaku (2025) Package Insert for ELZONRIS\u00ae I.V. Injection. (Japanese). https:\/\/med.nippon-shinyaku.co.jp\/product\/elzonris\/doc\/doc_elzonris\/. Accessed 23 Dec 2025"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02955-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02955-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02955-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:03:41Z","timestamp":1771952621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02955-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":7,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2955"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02955-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"8 January 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No author has any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}